Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07449910
PHASE2/PHASE3

Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial

Sponsor: The First Affiliated Hospital of University of Science and Technology of China

View on ClinicalTrials.gov

Summary

The primary purpose of this study is to evaluate the efficacy and safety of Baricitinib combined with endovascular therapy in patients with acute anterior circulation large vessel occlusion, to address futile recanalization with priority, and to elucidating the mechanism of JAK/STAT pathway inhibition on neuroprotection and inflammatory regulation.

Official title: Safety and Efficacy of Baricitinib Combined With Acute Large Vessel Occlusion Recanalization : A Multicenter, Randomized Controlled Clinical Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

750

Start Date

2026-03-17

Completion Date

2028-01-31

Last Updated

2026-03-04

Healthy Volunteers

No

Interventions

DRUG

2mg Baricitinib

One 2mg Baricitinib tablet and one 2mg placebo tablet are given three times a day, last for 5±2 days.

DRUG

4mg Baricitinib

Two 2mg Baricitinib tablets are given three times a day, last for 5±2 days.

DRUG

Placebo

Two 2mg placebo tablets are given three times a day, last for 5±2 days.

OTHER

Guideline-based therapy

Guideline-based therapy including EVT treatment is determined by the physician.

Locations (1)

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Recruiting

Hefei, Anhui, China